A Phase II Trial of TAS-102 in Colorectal Cancer Patients with ctDNA-defined Minimal Residual Disease Post-Adjuvant Therapy: Results from th Published Date January 22, 2024 Expand Fullscreen Exit Fullscreen Download PDF Expand Fullscreen